Pimavanserin

Drug Profile

Pimavanserin

Alternative Names: ACP-103; BVF-048; Nuplazid; Pimavanserin tartrate

Latest Information Update: 30 Dec 2016

Price : $50

At a glance

  • Originator ACADIA Pharmaceuticals
  • Class Antiparkinsonians; Antipsychotics; Piperidines; Small molecules
  • Mechanism of Action Serotonin 2A receptor inverse agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Psychotic disorders
  • Phase III Schizophrenia
  • Phase II Agitation; Major depressive disorder
  • Discontinued Drug-induced akathisia; Drug-induced dyskinesia; Insomnia

Most Recent Events

  • 20 Dec 2016 Topline efficacy data from phase II trials in Psychotic disorders (Alzheimer's disease-associated psychosis) released by ACADIA Pharmaceuticals
  • 01 Dec 2016 Phase-II clinical trials in Major depressive disorder (Adjunctive treatment, Treatment-experienced) in USA (PO)
  • 15 Nov 2016 ACADIA Pharmaceuticals initiates the phase II ADVANCE trial in Schizophrenia (negative symptoms; Adjunctive treatment) in USA (PO, Tablet) (9207145; NCT02970305)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top